Select therapeutic use:

Arthritis/rheumatic disorders:

Indications for: SKYRIZI

Active psoriatic arthritis.

Adult Dosage:

Administer by SC inj into abdomen, thighs (or may be given by healthcare provider only in upper, outer arm). ≥18yrs: 150mg by SC inj at Week 0, Week 4, and every 12 weeks thereafter. May be given alone or in combination with non-biologic DMARDs.

Children Dosage:

<18yrs: not established.

SKYRIZI Warnings/Precautions:

Use under physician supervision and guidance. Discontinue if serious hypersensitivity reactions (eg, anaphylaxis) occur; treat appropriately. Increased risk of infections. Active infection: do not initiate until resolves or treated. Chronic or history of recurrent infection: consider risks/benefits. Evaluate for tuberculosis (TB) infection prior to initiation. History of latent or active TB (without confirmed adequate treatment); consider anti-TB therapy prior to initiating. Monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. Complete all immunizations according to current guidelines prior to initiation. For Crohn disease: obtain liver enzymes, bilirubin levels prior to initiation and during induction at least up to 12 weeks of treatment. Interrupt therapy if drug-induced liver injury is suspected. Consider alternative treatment in those with evidence of liver cirrhosis. Pregnancy. Nursing mothers.

SKYRIZI Classification:

Interleukin-23 antagonist.

SKYRIZI Interactions:

Avoid use of live vaccines.

Adverse Reactions:

Upper respiratory infections, headache, fatigue, inj site reactions, tinea infections; hypersensitivity reactions.

Generic Drug Availability:

NO

How Supplied:

Single-dose prefilled syringe (75mg/0.83mL)—2 (w. supplies); Single-dose prefilled pen or syringe (150mg/mL)—1 (w. supplies); Single-dose prefilled cartridge (360mg/2.4mL)—1 (kit w. on-body injector); Single-dose vial (600mg/10mL)—1

Pricing for SKYRIZI

1 pen of 150mg/ml package (Qty: 1)
Appx. price $18028
GoodRx

Colorectal disorders:

Indications for: SKYRIZI

Moderately to severely active Crohn disease.

Adult Dosage:

≥18yrs: Induction: 600mg administered by IV infusion over at least 1hr at Week 0, Week 4, and Week 8. Complete infusion within 8hrs of dilution. Maintenance: 360mg administered by SC inj into thigh or abdomen (using the on-body injector) at Week 12, and every 8 weeks thereafter.

Children Dosage:

<18yrs: not established.

SKYRIZI Warnings/Precautions:

Use under physician supervision and guidance. Discontinue if serious hypersensitivity reactions (eg, anaphylaxis) occur; treat appropriately. Increased risk of infections. Active infection: do not initiate until resolves or treated. Chronic or history of recurrent infection: consider risks/benefits. Evaluate for tuberculosis (TB) infection prior to initiation. History of latent or active TB (without confirmed adequate treatment); consider anti-TB therapy prior to initiating. Monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. Complete all immunizations according to current guidelines prior to initiation. For Crohn disease: obtain liver enzymes, bilirubin levels prior to initiation and during induction at least up to 12 weeks of treatment. Interrupt therapy if drug-induced liver injury is suspected. Consider alternative treatment in those with evidence of liver cirrhosis. Pregnancy. Nursing mothers.

SKYRIZI Classification:

Interleukin-23 antagonist.

SKYRIZI Interactions:

Avoid use of live vaccines.

Adverse Reactions:

Upper respiratory infections, headache, arthralgia, inj site reactions, abdominal pain, anemia, pyrexia, back pain, arthropathy, urinary tract infection; hypersensitivity reactions, hepatotoxicity.

Generic Drug Availability:

NO

How Supplied:

Single-dose prefilled syringe (75mg/0.83mL)—2 (w. supplies); Single-dose prefilled pen or syringe (150mg/mL)—1 (w. supplies); Single-dose prefilled cartridge (360mg/2.4mL)—1 (kit w. on-body injector); Single-dose vial (600mg/10mL)—1

Pricing for SKYRIZI

1 pen of 150mg/ml package (Qty: 1)
Appx. price $18028
GoodRx

Psoriasis:

Indications for: SKYRIZI

Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Adult Dosage:

Administer by SC inj into abdomen, thighs (or may be given by healthcare provider only in upper, outer arm). ≥18yrs: 150mg by SC inj at Week 0, Week 4, and every 12 weeks thereafter.

Children Dosage:

<18yrs: not established.

SKYRIZI Warnings/Precautions:

Use under physician supervision and guidance. Discontinue if serious hypersensitivity reactions (eg, anaphylaxis) occur; treat appropriately. Increased risk of infections. Active infection: do not initiate until resolves or treated. Chronic or history of recurrent infection: consider risks/benefits. Evaluate for tuberculosis (TB) infection prior to initiation. History of latent or active TB (without confirmed adequate treatment); consider anti-TB therapy prior to initiating. Monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. Complete all immunizations according to current guidelines prior to initiation. For Crohn disease: obtain liver enzymes, bilirubin levels prior to initiation and during induction at least up to 12 weeks of treatment. Interrupt therapy if drug-induced liver injury is suspected. Consider alternative treatment in those with evidence of liver cirrhosis. Pregnancy. Nursing mothers.

SKYRIZI Classification:

Interleukin-23 antagonist.

SKYRIZI Interactions:

Avoid use of live vaccines.

Adverse Reactions:

Upper respiratory infections, headache, fatigue, inj site reactions, tinea infections; hypersensitivity reactions.

Generic Drug Availability:

NO

How Supplied:

Single-dose prefilled syringe (75mg/0.83mL)—2 (w. supplies); Single-dose prefilled pen or syringe (150mg/mL)—1 (w. supplies); Single-dose prefilled cartridge (360mg/2.4mL)—1 (kit w. on-body injector); Single-dose vial (600mg/10mL)—1

Pricing for SKYRIZI

1 pen of 150mg/ml package (Qty: 1)
Appx. price $18028
GoodRx